In 2020 the “Grindeks” Group has achieved the historically sharpest increase in turnover and profit
In 2020 the “Grindeks” Group has achieved the historically sharpest increase in turnover and profit. The consolidated, preliminary financial data of the Group show that in 2020 the turnover of the “Grindeks” Group reached
In 2020 the “Grindeks” Group has strengthened its positions in the global pharmacy market and exported its products to 93 countries for the total amount of
Ph. D.
In 2021 the “Grindeks” Group plans to increase the turnover by 19%.
Global expansion in new markets and strengthening positions in the existing markets
The sales volume of the Group's final dosage forms in 2020 was
The sales volume in
In 2020 the sales volume of the Group's final dosage forms in the
In 2020 the sales volume of the active pharmaceutical ingredients amounted to
The strategic goal of the Group is expanding operation in the
Covid-19 obstacles provide new opportunities
Similar as other companies, the “Grindeks” Group also rearranged its economic activities in 2020 due to the impact of the spread of Covid-19 virus. In order to overcome the operating obstacles caused by Covid-19, the Group defined three priorities: health protection and safety of the personnel, ensuring health needs of the patients and continued economic activity.
Covid-19 pandemics has changed the needs of the patients, therefore, the production process was rearranged to meet the growing demand and allow producing more. The ability to operate under extraordinary situation and quickly respond to growing demand encouraged activity in new markets –
Health care solutions for contemporary requirements and dynamic lifestyle
Business strategy 2025 envisages significant expansion of the “Grindeks” product range by adding advanced medicines for treating cardiovascular, central nervous system, oncological diseases and diabetes, as well as “Kalceks” medicines for hospital use. 51 new “Grindeks” and 35 new “Kalceks” medicines are under development.
“Grindeks” constantly produces 25 active pharmaceutical ingredients and has accumulated knowledge in the field of active pharmaceutical ingredients business for many years. It is the unique feature and competitive advantage of the Group. Development of this segment increases the independence of the Group from raw material manufacturers, which in the future will result in a benefit of Latvian and even
Development of the subsidiary “Kalceks”
In 2020 JSC “Kalceks”, which is the subsidiary of “Grindeks”, specializing in medicines for hospital use, achieved sharp increase in sales volumes by increasing the number of export countries and introducing new products. In 2020 “Kalceks” products were sold in the amount of
Expanding the production infrastructure
“Grindeks” has started to develop a project for construction of a new pharmaceuticals production plant in
Pharmaceutical forms those are not currently manufactured in
If the construction project will be successfully approved, the construction of the new production plant is due to begin in 2022.
Kirovs Lipmans, the Chairman of the
About “Grindeks” Group
“Grindeks” is an international pharmaceutical Group, and its main activities are research, development, production and sale of original products, generic medicines and active pharmaceutical ingredients.
The “Grindeks” Group consists of JSC “Grindeks” and its companies: JSC “Kalceks” in
The main therapeutic groups of “Grindeks” are cardiovascular, central nervous system, anti-cancer and diabetes medicines. “Kalceks” specializes in medicines for the hospital segment. The product range consists of the original products Mildronate® (meldonium) and Ftorafur® (tegafur), generics as well as active pharmaceutical ingredients.
In 2020 the Group exported its products to 93 countries. Major “Grindeks” markets are the
Contacts:
Laila Klavina, Head of
Phone.: 67083370, 29256012
E-mail: laila.klavina@grindeks.lv
www.grindeks.eu
© OMX, source